159 related articles for article (PubMed ID: 36513193)
1. The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Qin X; Xie C; Hakenjos JM; MacKenzie KR; Boyd SR; Barzi M; Bissig KD; Young DW; Li F
Eur J Pharm Sci; 2023 Feb; 181():106358. PubMed ID: 36513193
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.
Qin X; Hakenjos JM; MacKenzie KR; Barzi M; Chavan H; Nyshadham P; Wang J; Jung SY; Guner JZ; Chen S; Guo L; Krishnamurthy P; Bissig KD; Palmer S; Matzuk MM; Li F
Drug Metab Dispos; 2022 Feb; 50(2):128-139. PubMed ID: 34785568
[TBL] [Abstract][Full Text] [Related]
3. Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans.
Ngo TL; Lee CH; Han N; Back HM; Rhee SJ; Noh K; Yun HY; Kang W; Chae JW
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182820
[TBL] [Abstract][Full Text] [Related]
4. The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.
Kuzin M; Scharrer I; Nolan D; Baumgartner M; Paulzen M; Schoretsanitis G; Xepapadakos F
Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):354-357. PubMed ID: 32365274
[No Abstract] [Full Text] [Related]
5. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
[TBL] [Abstract][Full Text] [Related]
7. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine: clinical pharmacokinetics and drug interactions.
Knadler MP; Lobo E; Chappell J; Bergstrom R
Clin Pharmacokinet; 2011 May; 50(5):281-94. PubMed ID: 21366359
[TBL] [Abstract][Full Text] [Related]
9. The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression.
Maciaszek J; Pawłowski T; Hadryś T; Machowska M; Wiela-Hojeńska A; Misiak B
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686266
[TBL] [Abstract][Full Text] [Related]
10. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
12. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
Paulzen M; Finkelmeyer A; Grözinger M
Pharmacopsychiatry; 2011 Nov; 44(7):317-23. PubMed ID: 21979923
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
16. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Miksys SL; Cheung C; Gonzalez FJ; Tyndale RF
Drug Metab Dispos; 2005 Oct; 33(10):1495-502. PubMed ID: 16033950
[TBL] [Abstract][Full Text] [Related]
17. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
18. CYP2D plays a major role in berberine metabolism in liver of mice and humans.
Guo Y; Li F; Ma X; Cheng X; Zhou H; Klaassen CD
Xenobiotica; 2011 Nov; 41(11):996-1005. PubMed ID: 21787170
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
[TBL] [Abstract][Full Text] [Related]
20. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
Abduljalil K; Pansari A; Jamei M
J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
